BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Alpelisib (BYL719) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Alpelisib (BYL719)\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05563220-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Alpelisib (BYL719): Phase 1/2 readout est. (NCT05563220)
DESCRIPTION:Alpelisib (BYL719)\, phase 1/2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of
  Elacestrant In Various Combination In Participants With Metastatic Breast
  Cancer\nEstimated primary completion: 27 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05563220
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06354088-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alpelisib (BYL719): Phase 1 readout est. (NCT06354088)
DESCRIPTION:Alpelisib (BYL719)\, phase 1.\nStudy: Human Models of Selective
  Insulin Resistance: Alpelisib\, Part I\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/alpeli
 sib-byl719#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06354088
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06739395-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT06739395)
DESCRIPTION:Alpelisib (BYL719)\, phase 2.\nStudy: Precision Medicine Trial 
 Based on Molecular Matching Therapy for Patients With Standard Treatment E
 xhaustion\nEstimated primary completion: 31 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06739395
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05983159-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT05983159)
DESCRIPTION:Alpelisib (BYL719)\, phase 2.\nStudy: A Trial of Targeted Thera
 pies for Patients With Slow-Flow or Fast-Flow Vascular Malformations\nEsti
 mated primary completion: January 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05983159
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05038735-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20270128
DTEND;VALUE=DATE:20270129
SUMMARY:Alpelisib (BYL719): Phase 3 readout est. (NCT05038735)
DESCRIPTION:Alpelisib (BYL719)\, phase 3\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Study to Assess the Efficacy and Safety of Alpelisib Plus Fulv
 estrant in Participants With HR-positive (HR+)\, HER2-negative\, Advanced 
 Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inh
 ibitor.\nEstimated primary completion: 28 January 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05038735
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04544189-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT04544189)
DESCRIPTION:Alpelisib (BYL719)\, phase 2\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Study Assessing the Efficacy and Safety of Treatment With Alpe
 lisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and 
 Postmenopausal Women With Advanced Breast Cancer\nEstimated primary comple
 tion: 29 January 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/alpelisib-byl719#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04544189
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01872260-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Alpelisib (BYL719): Phase 1/2 readout est. (NCT01872260)
DESCRIPTION:Alpelisib (BYL719)\, phase 1/2\, HR+/HER2- Metastatic Breast Ca
 ncer.\nStudy: Study of LEE011\, BYL719 and Letrozole in Advanced ER+ Breas
 t Cancer\nEstimated primary completion: 26 February 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT01872260
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04524000-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT04524000)
DESCRIPTION:Alpelisib (BYL719)\, phase 2\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Study Assessing the Efficacy and Safety of Treatment With Alpe
 lisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advan
 ced Breast Cancer\nEstimated primary completion: 26 February 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04524000
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04208178-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Alpelisib (BYL719): Phase 3 readout est. (NCT04208178)
DESCRIPTION:Alpelisib (BYL719)\, phase 3\, Breast Cancer.\nStudy: Study of 
 Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maint
 enance Therapy in Patients With HER2-positive Advanced Breast Cancer With 
 a PIK3CA Mutation\nEstimated primary completion: 26 February 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04208178
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05577754-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT05577754)
DESCRIPTION:Alpelisib (BYL719)\, phase 2.\nStudy: Assessment of the Efficac
 y and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Me
 galencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)\nEstima
 ted primary completion: March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/alpelisib-byl719#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05577754
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04980833-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20270622
DTEND;VALUE=DATE:20270623
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT04980833)
DESCRIPTION:Alpelisib (BYL719)\, phase 2.\nStudy: Study Assessing Long-term
  Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrow
 th Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPI
 K-P1)\nEstimated primary completion: 22 June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04980833
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06545682-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20270803
DTEND;VALUE=DATE:20270804
SUMMARY:Alpelisib (BYL719): Phase 1 readout est. (NCT06545682)
DESCRIPTION:Alpelisib (BYL719)\, phase 1\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients Wit
 h mEtastatic Breast caNcer or melanomA (SELENA)\nEstimated primary complet
 ion: 3 August 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 lpelisib-byl719#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06545682
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT02925234)
DESCRIPTION:Alpelisib (BYL719)\, phase 2.\nStudy: The Drug Rediscovery Prot
 ocol (DRUP Trial)\nEstimated primary completion: September 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05090358-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20271008
DTEND;VALUE=DATE:20271009
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT05090358)
DESCRIPTION:Alpelisib (BYL719)\, phase 2\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Preventing High Blood Sugar in People Being Treated for Metast
 atic Breast Cancer\nEstimated primary completion: 8 October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05090358
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05508906-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Alpelisib (BYL719): Phase 1 readout est. (NCT05508906)
DESCRIPTION:Alpelisib (BYL719)\, phase 1\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Phase 1b Study of OP-1250 (Palazestrant) in Combination With R
 ibociclib\, Alpelisib\, Everolimus\, or Atirmociclib in ER+\, HER2- Breast
  Cancer\nEstimated primary completion: 31 December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05508906
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05154487-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT05154487)
DESCRIPTION:Alpelisib (BYL719)\, phase 2.\nStudy: A Study of Alpelisib and 
 Fulvestrant to Treat Endometrial Cancer\nEstimated primary completion: 1 M
 ay 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/alpelisib-by
 l719#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05154487
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05948943-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Alpelisib (BYL719): Phase 2/3 readout est. (NCT05948943)
DESCRIPTION:Alpelisib (BYL719)\, phase 2/3.\nStudy: Alpelisib in Pediatric 
 and Adult Patients With Lymphatic Malformations Associated With a PIK3CA M
 utation.\nEstimated primary completion: 31 May 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05948943
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06145308-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT06145308)
DESCRIPTION:Alpelisib (BYL719)\, phase 2.\nStudy: Precision Treatment of Re
 current/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing\nEs
 timated primary completion: 10 July 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06145308
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07778524-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Alpelisib (BYL719): Phase 1 readout est. (NCT07778524)
DESCRIPTION:Alpelisib (BYL719)\, phase 1.\nStudy: Alpelisib Challenge Test 
 (ACT)\nEstimated primary completion: 31 August 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07778524
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06997588-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20290129
DTEND;VALUE=DATE:20290130
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT06997588)
DESCRIPTION:Alpelisib (BYL719)\, phase 2.\nStudy: EPIK-P4: A Phase II Singl
 e-arm Study to Assess the Efficacy\, Safety and Pharmacokinetics of Alpeli
 sib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowt
 h Spectrum (PROS)\nEstimated primary completion: 29 January 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06997588
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07543822-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20291027
DTEND;VALUE=DATE:20291028
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT07543822)
DESCRIPTION:Alpelisib (BYL719)\, phase 2.\nStudy: 24VA022\; VATCH Alpelisib
  for TIE2/PIK3CA Pathway VAs\nEstimated primary completion: 27 October 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/alpelisib-byl719#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07543
 822
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564377-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT05564377)
DESCRIPTION:Alpelisib (BYL719)\, phase 2\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Targeted Therapy Directed by Genetic Testing in Treating Patie
 nts With Locally Advanced or Advanced Solid Tumors\, The ComboMATCH Screen
 ing Trial\nEstimated primary completion: 1 July 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05564377
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05933395-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT05933395)
DESCRIPTION:Alpelisib (BYL719)\, phase 2\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6
  Inhibitor\nEstimated primary completion: October 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05933395
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679269-3247@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20320323
DTEND;VALUE=DATE:20320324
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT07679269)
DESCRIPTION:Alpelisib (BYL719)\, phase 2\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Roll-Over Study of Alpelisib (BYL719) for Continued Access and
  Long-Term Safety.\nEstimated primary completion: 23 March 2032. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07679269
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
